Target Information

Target General Infomation
Target ID
T00145
Target Name
HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
Target Status
Target in Phase 3 Trial
 [1]
Disease [+] 1 Target-related Diseases +
1 COVID-19 [ICD-11: 1D6Y]
Drugs and Modes of Action
Drugs in Phase 3 Trial [+] 6 Drugs in Phase 3 Trial +
1 Darunavir + ritonavir + oseltamivir + hydroxychloroquine Drug Info Phase 3 Trial COVID-19 [2]
2 Chloroquine Drug Info Phase 3 Trial COVID-19 [3]
3 Oseltamivir + hydroxychloroquine Drug Info Phase 3 Trial COVID-19 [2]
4 Azithromycin + hydroxychloroquine Drug Info Phase 3 Trial COVID-19 [4]
5 Darunavir + ritonavir + favipiravir + hydroxychloroquine Drug Info Phase 3 Trial COVID-19 [2]
6 Hydroxychloroquine Drug Info Phase 3 Trial COVID-19 [5], [6]
Mode of Action [+] 1 Modes of Action +
Inhibitor [+] 6 Inhibitor drugs +
1 Azithromycin + hydroxychloroquine Drug Info [1], [7]
2 Chloroquine Drug Info [1], [7]
3 Darunavir + ritonavir + favipiravir + hydroxychloroquine Drug Info [1], [7]
4 Darunavir + ritonavir + oseltamivir + hydroxychloroquine Drug Info [1], [7]
5 Hydroxychloroquine Drug Info [1], [7]
6 Oseltamivir + hydroxychloroquine Drug Info [1], [7]
References
1 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
2 ClinicalTrials.gov (NCT04303299) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial
3 ClinicalTrials.gov (NCT04360759) Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04321278) Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04341727) Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection (WU352). U.S. National Institutes of Health.
6 Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020. April. 01; 369:m1335
7 Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020 Apr;15(4):247-249.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.